165 related articles for article (PubMed ID: 25787775)
1. Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer.
Ideo H; Hinoda Y; Sakai K; Hoshi I; Yamamoto S; Oka M; Maeda K; Maeda N; Hazama S; Amano J; Yamashita K
Int J Cancer; 2015 Oct; 137(7):1652-60. PubMed ID: 25787775
[TBL] [Abstract][Full Text] [Related]
2. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
3. Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.
Seko A; Ohkura T; Ideo H; Yamashita K
Glycobiology; 2012 Feb; 22(2):181-95. PubMed ID: 21880669
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of a high-affinity monoclonal antibody for MUC1 measurement in breast cancer.
Hamid SS; Cheah SH
Hybridoma (Larchmt); 2011 Apr; 30(2):137-43. PubMed ID: 21529286
[TBL] [Abstract][Full Text] [Related]
5. The HCCR oncoprotein as a biomarker for human breast cancer.
Jung SS; Park HS; Lee IJ; Namkoong H; Shin SM; Cho GW; Ha SA; Park YG; Lee YS; Ko J; Kim JW
Clin Cancer Res; 2005 Nov; 11(21):7700-8. PubMed ID: 16278390
[TBL] [Abstract][Full Text] [Related]
6. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
7. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
9. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
10. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
[TBL] [Abstract][Full Text] [Related]
11. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer.
Ali HQ; Mahdi NK; Al-Jowher MH
J Pak Med Assoc; 2013 Sep; 63(9):1138-41. PubMed ID: 24601193
[TBL] [Abstract][Full Text] [Related]
12. Development and application of a double- antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients.
Wang J; Zhang S; Ni W; Zhai X; Xie F; Yuan H; Gao S; Tai G
Cancer Biomark; 2016; 17(4):369-376. PubMed ID: 27636855
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
15. The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status.
Hashim ZM
Int J Immunopathol Pharmacol; 2014; 27(1):45-51. PubMed ID: 24674678
[TBL] [Abstract][Full Text] [Related]
16. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
17. Automated immunofluorometric assay for MUC1.
Norum LF; Nilsson O; Nustad K
Tumour Biol; 2001; 22(3):169-75. PubMed ID: 11275795
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
19. Expression of Vicia villosa agglutinin (VVA)-binding glycoprotein in primary breast cancer cells in relation to lymphatic metastasis: is atypical MUC1 bearing Tn antigen a receptor of VVA?
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T; Kanno M; Igarashi S
Breast Cancer Res Treat; 2006 Jul; 98(1):31-43. PubMed ID: 16752227
[TBL] [Abstract][Full Text] [Related]
20. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
Alix-Panabières C; Brouillet JP; Fabbro M; Yssel H; Rousset T; Maudelonde T; Choquet-Kastylevsky G; Vendrell JP
J Immunol Methods; 2005 Apr; 299(1-2):177-88. PubMed ID: 15914200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
